Zymeworks Inc. (ZYME)
After hours:
| Previous close | 11.55 |
| Open | 11.43 |
| Bid | 11.10 x 800 |
| Ask | 17.99 x 1100 |
| Day's range | 11.00 - 11.68 |
| 52-week range | 11.00 - 51.19 |
| Volume | |
| Avg. volume | 803,154 |
| Market cap | 521.87M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.45 |
| Earnings date | 22 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.38 |
- Business Wire
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
VANCOUVER, British Columbia & SEATTLE, January 19, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.
- Zacks
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks
RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.
- Business Wire
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
VANCOUVER, British Columbia & SEATTLE, January 15, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the "NYSE Rule"), an equity inducement award to Mr. Kenneth Galbraith, Zymeworks’ new Chair, President and Chief Executive Officer.
